MedPath

To compare the postoperative pain relief in laparoscopic cholecystectomy by bilateral transverse abdominal plane block and giving the drug intraperitoneal along with skin infiltration.

Not yet recruiting
Conditions
Calculus of gallbladder with acutecholecystitis,
Registration Number
CTRI/2022/06/043353
Lead Sponsor
SRM Medical College Hospital
Brief Summary

120 patient who meet the inclusion criteria will be allocated into 2 groups by computer generated randomization.

GROUP :A    Ultrasound guided Subcostal TAP Block

GROUP :B    Port site infiltration and intraperitoneal instillation.

All patients will be premedicated with tab.Alprazolam 0.5 mg preoperatively ,2 hours before shifting to operation theatre. Patients vitals will be monitored with pulse oximetry ,NIBP and ECG.

All patients will receive general anesthesia with endotracheal intubation which will be standardized

Patients will be induced with Propofol 2 mg /kg and Vecuronium 0.1 mg/kg as the muscle relaxant . Fentanyl 2 mcg/kg will be used as the intraoperative analgesia. Anesthesia will be maintained with Sevoflurane and Vecuronium.

After induction of anesthesia , the patient will receive either ultrasound -guided bilateral subcostal TAP Block(GROUP:A) or the combination of port site infiltration and intraperitoneal instillation(GROUP:B)

GROUP:A Bilateral Subcostal TAP Block will be performed under ultrasound vision ( Logic V2 GE Ultrasound ), using a 6 to 15- HZ high - frequency linear probe and a 100- mm needle with the patient lying in supine decubitus position. 20 ml of 0,25 % Ropivacaine will be deposited in each side.

GROUP:B 5 ml of 0.25% Ropivacaine will be infiltrated in each port site before insertion of the trochar. In addition after creation of pneumoperitoneum , the operating surgeon will be asked to instill 20 ml of 0.25% Ropivacaine propotionately over the gall bladder, liver surface and the patient peritoneum on the undersurface of the diaphragm before starting the dissection.

The patient will be extubated at the end of surgery and shifted to recovery. The patient will be shifted to PACU when Aldrete recovery criteria are satisfied .The patient will be continiously monitored in PACU for 24 hours.

The pain will be assessed by Visual Analog Scale

0  :  NO PAIN

1-2   :  MILD PAIN INTENSITY

3-5  : MODERATE PAIN INTENSITY

6-8  : SEVERE PAIN INTENSITY

9-10 : WORST PAIN

The duration of postoperative analgesia is defined as the time taken from the completion of block or infiltration to the first request for the postoperative analgesia (VAS >3)

The patient will be started on the patient control analgesia  using morphine with a bolus dose of 1mg and lockout interval of 10 minutes.

The total consumption of morphine will be noted . The occurance of any adverse effects like nausea , Vomiting , itching and respiratory depression will be noted and treated accordingly

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
120
Inclusion Criteria

1.Patients with ASA Physical Status I and II posted for laparoscopic cholecystectomy 2.Weighing between 50 – 100 kg.

Exclusion Criteria

1.All patients with ASA Physical Status III and above 2.Patients who refuse to participate in the study 3.Patients who are allergic to amide local anaesthetics 4.Patients who are pregnant 5.Patients with chronic cardiac, renal or hepatic condition 6.Patients with coagulation abnormalities.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To estimate the duration of postoperative analgesiapatient is assessed for pain second hourly using Visual Analogue Scale for 24 hours
Secondary Outcome Measures
NameTimeMethod
1.To estimate the Consumption of morphine in 24 hour postoperative period2.Intraoperative consumption of opioids

Trial Locations

Locations (1)

SRM Hospital

🇮🇳

Kancheepuram, TAMIL NADU, India

SRM Hospital
🇮🇳Kancheepuram, TAMIL NADU, India
DRRBALAJI
Principal investigator
9677053310
aarbee79@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.